Comparison of 5-Fluorouracil, Doxorubicin and Mitomycin C with 5-Fluorouracil Alone in the Treatment of Pancreatic-Biliary Carcinomas

Takada, Tadahiro; Kato, Hiroyuki; Matsushiro, Takashi; Nimura, Yuji; Nagakawa, Takukazu; Nakayama, Toshimichi

doi:10.1159/000227373

Cited by 91 publications

(42 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the what to our knowledge is the first study of 5-FU monotherapy compared with modified FAM therapy, patients with gallbladder carcinoma who received modified FAM therapy demonstrated improvements in PS and symptoms, and had a tendency toward longer survival. 30 In the second study of FAM therapy, in which a half-dose level (1/2 FAM) was used in comparison with best supportive care, 1/2 FAM therapy demonstrated a significantly longer time to disease progression, but only in gallbladder carcinoma patients. 31 These findings suggest that the results of drug sensitivity testing described earlier, as well as the results from our previous two clinical trials of patients with nonresected disease, support to some extent the results of the current study, which indicate a significantly prolonged survival time in gallbladder carcinoma patients only.…”

Section: Discussionmentioning

confidence: 99%

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?

Takada

Amano

Yasuda

et al. 2002

Cancer

Self Cite

561

135

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?

Takada

Amano

Yasuda

et al. 2002

Cancer

Self Cite

561

135

View full text Add to dashboard Cite

show abstract

“…As with other gastrointestinal cancers, 5-fluorouracil (5-FU) as a single agent or in combination is the most tested drug for this disease. The wide range of activity of a 5-FU based regimen had been reported to range from 0% to 30% [1][2][3] . Many studies included a heterogeneous group of patients, with tumors arising from different anatomic sites along the biliary tract such as gall bladder cancer, periampullary cancer and cholangiocarcinoma, which may have a different biology and sensitivity to chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma

Charoentum¹,

Thongprasert²,

Chewaskulyong³

et al. 2007

WJG

View full text Add to dashboard Cite

AIM:To study the activity of gemcitabine and cisplatin in a cohort of patients with inoperable or metastatic cholangiocarcinoma. METHODS:C h e m o t h e ra p y-n a i v e p a t i e n t s w i t h pathologically proven cholangiocarcinoma, receiving treatment that consisted of gemcitabine at 1250 mg/m 2 in a 30-min infusion on d 1 and 8, and cisplatin at 75 mg/m 2 at every 21-d cycle, were retrospectively analyzed. RESULTS:From June 2003 to December 2005, 42 patients were evaluated. Twelve patients (28%) had unresectable disease and 30 (72%) had metastatic disease. There were 28 males and 14 females with a median age of 51 years (range 33-67) and median ECOG PS of 1 (range 0-2). A total of 171 cycles were given with a median number of cycles of 4 (range 1-6). There were 0 CR, 9 PR, 11 SD and 13 PD (response rate 21%). Grade 3-4 hematologic toxicities were: anemia in 33%, neutropenia in 22% and thrombocytopenia in 5%. Non-hematologic toxicity was generally mild. No cases of febrile neutropenia or treatment-related death were noted. The median survival was 10.8 mo (range 8.4-13 mo) and progression free survival was 8.5 mo. One-year survival rate was 40%. C O N C L U S I O N :O u r r e s u l t s i n d i c a t e t h a t t h e combination of gemcitabine and cisplatin had consistent efficacy in patients with unresectable or metastatic cholangiocarcinoma.

show abstract

“…In general, 5-FU has produced few responses. 7,8 However, several recent small trials have suggested that highdose 5-FU or 5-FU in combination with other agents may produce partial responses (PR) in up to one-third of patients. 9 -12 Several case reports have suggested that gemcitabine may have activity in biliary tract and gallbladder carcinomas.…”

mentioning

confidence: 99%

Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma

Alberts

Alkhatib

Mahoney

et al. 2004

Cancer

114

View full text Add to dashboard Cite

BACKGROUNDGemcitabine has broad activity in a variety of solid tumors including biliary tract carcinomas. The authors evaluated 6‐month survival, response, and toxicity associated with a combination of gemcitabine, 5‐fluorouracil (5‐FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA).METHODSA 4‐week course included 1000 mg/m2 gemcitabine by intravenous infusion over 30 minutes on Days 1, 8, and 15, 25 mg/m2 LV by intravenous push, and 600 mg/m2 5‐FU by intravenous push after LV.RESULTSForty‐two patients were enrolled in 6 months, 35 of whom had metastatic disease. Patients with biliary tract ACA included 24 with hepatic disease (19 patients had intrahepatic disease and 5 patients had extrahepatic disease) and 4 with disease in the ampulla of Vater. All patients were evaluable and received a median of 4 courses of treatment (range, 1–21 courses). Commonly occurring severe toxicity (NCI CTC Grade 3 or worse) included: dyspnea (four patients), nausea (four patients), fatigue (seven patients), thrombocytopenia (six patients), emesis (four patients), and diarrhea (four patients). Five partial responses (9.5%) occurred, 3 of which were sustained for ≥ 8 weeks. No treatment‐related deaths occurred. Thirty‐two patients had disease progression and 38 died after a median follow‐up of 20 months (range, 1.4–24 months). The median time to disease progression was 4.6 months (95% confidence interval [95% CI], 2.4–6.6%). The median survival period was 9.7 months (95% CI, 7–12%).CONCLUSIONSThis combination regimen was manageable in patients with advanced biliary tract and gallbladder ACA. Of 42 patients, 24 (57%) survived ≥ 6 months, satisfying the primary end point of the trial. The length of survival suggested that gemcitabine, 5‐FU, and LV had benefit equivalent to gemcitabine alone. Cancer 2005. © 2004 American Cancer Society.

show abstract

Comparison of 5-Fluorouracil, Doxorubicin and Mitomycin C with 5-Fluorouracil Alone in the Treatment of Pancreatic-Biliary Carcinomas

Cited by 91 publications

References 6 publications

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?

Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma

Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma

Contact Info

Product

Resources

About